Subscribe
Subscribe today to receive CGD’s latest newsletters and topic updates.
All Commentary
Filters:
Topics
Facet Toggle
Content Type
Facet Toggle
Time Frame
Facet Toggle
Blog Post
December 16, 2015
The first thing we should be asking is why now in particular, since conditions have not really changed much in the past few months. For example, back in September, there were large uncertainties in the global economy. China’s economic slowdown was causing alarm. Volatility in international cap...
Blog Post
December 15, 2015
Those who follow CGD will be familiar with our branded meme: “Cash on Delivery” aid, or COD. Many are enthusiastic about COD’s potential to revolutionize aid effectiveness. Yet within some global development organizations, leadership and staff alike express common concerns: is...
Blog Post
December 01, 2015
As it does every year at this time, UNAIDS has released its World AIDS Day report. With five out of seven HIV infected people living in Africa, it is appropriate that the report is released here at the International Conference on AIDS and STIs in Africa (ICASA) in Harare, Zimbabwe.
Blog Post
November 17, 2015
The Latin American Shadow Regulatory Committee, known as CLAAF for its Spanish acronym, warns today in its biannual statement that despite positive policies and safeguards, the region is facing external and local risks that could affect its economic and financial outlook.
Blog Post
November 10, 2015
Financial inclusion is a key development focus in Turkey’s agenda for the G-20 summit beginning this weekend (November 15). I am pleased to note that the international community’s efforts to broaden financial inclusion have continued to gain momentum since the 2010 G-20 Summit in Seoul, ...
Blog Post
October 22, 2015
After Nancy Birdsall wrote from Lima last week that she’d been (happily) surprised to see microeconomic issues atop the agenda at the normally macro-heavy World Bank/IMF meetings, I now offer an alternative perspective from the meetings in the Peruvian capital: financial in...
Blog Post
September 23, 2015
You’ve probably already heard about the pharma outrage du jour. In short: start-up Turing Pharmaceuticals, led by combative ex-hedge fund manager Martin Shkreli, recently acquired Daraprim, a 60+ year-old drug to treat a parasitic infection called toxoplasmosis –...